Advances in pharmaceutic managements of migraine

Abstract

Migraine is a neurovascular disorder with great burden so that effective abortive and preventive treatment is needed. Different from the previous choice of drugs based on clinical experience, the specific treatment targeting the pathogenesis of migraine has revolutionized the management of migraine in recent years. Ditans and gepants can not only effectively relief headache and related symptoms but also be effective for those who are refractory to the abortive treatment by traditional painkillers or triptans. A variety of monoclonal antibodies against calcitonin gene⁃related peptide (CGRP) and CGRP receptor can effectively reduce headache attacks, especially when accompanied by other difficult clinical situations. This paper reviews the research progress of migraine drugs and its impact on clinical practice.

doi：10.3969/j.issn.1672⁃6731.2022.02.008